Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy.

Signal transduction and targeted therapy·2026

Same author

Comparison of Intravitreal Antivascular Endothelial Growth Factor Therapy in Treatment-Naïve vs Panretinal Photocoagulation-Treated Eyes With Proliferative Diabetic Retinopathy.

Journal of vitreoretinal diseases·2026

Same author

Saliva as a noninvasive diagnostic for ocular sarcoidosis.

Journal of leukocyte biology·2026

Same author

Oral cyclophosphamide as part of the treatment regimen in patients with nonparaneoplastic autoimmune retinopathy secondary to birdshot chorioretinopathy.

Oman journal of ophthalmology·2026

Same author

Real-world cost evaluation of conbercept vs. ranibizumab for retinal and choroidal vascular diseases from 2021 to 2024: evidence from societal and medical insurance perspectives.

BMC public health·2026

Same author

How to interpret low-dose valacyclovir for postherpetic neuralgia in the Zoster Eye Disease Study-a randomized clinical trial.

Annals of translational medicine·2026

Search research articles

Related Experiment Video

Updated: Mar 7, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL

Andres F Lasave^1,2, Caiyun You^1,2, Lina Ma^1,2

¹Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts.

Retina (Philadelphia, Pa.)

|February 23, 2017

Summary

Rituximab therapy effectively controlled inflammation and improved vision in patients with refractory noninfectious posterior uveitis. This treatment offers a stable remission option for those unresponsive to other therapies.

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Related Experiment Videos

Last Updated: Mar 7, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Area of Science:

Ophthalmology
Immunology

Background:

Noninfectious posterior uveitis is a challenging condition often requiring long-term management.
Refractory cases necessitate exploring alternative therapeutic strategies for sustained disease control.

Purpose of the Study:

To evaluate the long-term efficacy and safety of rituximab in treating noninfectious posterior uveitis.
To assess visual acuity outcomes and inflammatory markers following rituximab administration.

Main Methods:

Retrospective case series including patients with recalcitrant noninfectious posterior uveitis treated with rituximab.
Data collected on best-corrected visual acuity and fluorescein angiography findings at multiple time points up to 24 months.
Minimum follow-up duration of 24 months was required for inclusion.

Main Results:

Eleven patients (21 eyes) with refractory posterior uveitis were analyzed.
Significant improvement in best-corrected visual acuity from 20/80 to 20/40 (P = 0.005).
Inflammation control achieved in 81.8% of patients, with no significant adverse events reported.

Conclusions:

Rituximab demonstrates significant long-term effectiveness in managing refractory noninfectious posterior uveitis.
It provides a viable treatment option for patients who have failed or are intolerant to other therapies.
The therapy is associated with sustained remission and improved visual outcomes.